Clinical trials: Uncontrolled Type 1 Diabetes Mellitus
Diabetes
Efficacy and Safety of Frequently Modified Intensive Insulin
The purpose of this study is to evaluate the efficacy and safety of frequently modified intensive insulin therapy in patients with Type-2 and Type-1 diabetes mellitus.
- Trial name
- NCT01014832
- Testing
- Intensive insulin therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Hygieia, Inc
Diabetes Mellitus
Extension to Study HMR1964A/3011 in Belgium
The purpose of this trial is to allow patients to continue on HOE 901 until launch and to gather additional long-term safety data.
- Trial name
- NCT00576862
- Testing
- INSULIN GLARGINE
- Where
- Belgium
- Volunteers
- 32 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Primary objective: AT.LANTUS main study* To determine the optimal treatment algorithm for insulin glargine based on the incidence of severe hypoglycaemia.(*Target Number of patients for the main study:2346) HALT Sub-study** To…
- Trial name
- AT-LANTUS (NCT00390728)
- Testing
- Insulin Glargine
- Volunteers
- 2,346 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1 or 2
Safety and Efficacy of the GlucoMe APP in Patients With Uncontrolled Diabetes Treated With MDI
The study will evaluate the safety and efficacy of computerized GlucoMe App in patients with uncontrolled diabetes treated with MDI.
- Trial name
- NCT03017287
- Testing
- GlucoMe App
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- GlucoMe
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week) administration to Type 1 and Type 2 diabetes patients (non-smokers)
- Trial name
- NCT00527397
- Testing
- CP-464,005
- Where
- 10 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day, tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- SUBSTITUTE (NCT01204593)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 43 sites in Algeria, Argentina and 7 more
- Volunteers
- 206 people
- Sponsor
- Sanofi
Type I Diabetes Mellitus
Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL
Primary Objective: To evaluate the efficacy of switching treatment from twice-daily basal insulin to once-daily insulin glargine (U300) as part of basal bolus regime in terms of glycated hemoglobin improvement (reduction by at…
- Trial name
- TOP1 (NCT03406000)
- Testing
- INSULIN GLARGINE (U300)
- Where
- 11 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Observational Study With InnoLet® in Daily Clinical Practice
This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492959
- Testing
- insulin human
- Where
- South Korea
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus
This study is conducted in Europe. An observational study evaluating glycaemic control in patients using Levemir® as initiation insulin therapy as the treatment of type 2 diabetes in Slovakia.
- Trial name
- START (NCT00687284)
- Testing
- insulin detemir
- Where
- Slovakia
- Volunteers
- 2,188 people
- Sponsor
- Novo Nordisk A/S
Non-Insulin-Dependent Diabetes Mellitus
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
A better glycemic control is associated with less complications (cardiac diseases, blindness, etcetera) for type 2 diabetic patients.
- Trial name
- NCT00318656
- Testing
- rosiglitazone-metformin fixed dose combination, metformin + glimepiride
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline